肾移植受者人类微小病毒B19感染临床诊疗技术规范(2022版)

Technical specification for clinical diagnosis and treatment of human parvovirus B19 infection in kidney transplant recipients(2022 edition)

肾移植受者长期使用免疫抑制剂,导致其免疫功能低下,容易伴发各种病原体感染。近年来随着人类微小病毒B19(HPV-B19)感染的检测技术发展和肾移植手术的增多,肾移植术后HPV-B19的感染率呈逐年上升的趋势,是导致术后纯红细胞再生障碍性贫血的重要原因之一,影响移植肾功能恢复,甚至导致移植肾损伤或预后不良。为了进一步规范肾移植受者HPV-B19感染的诊断和治疗,中华医学会器官移植学分会和国家肾脏移植质控中心组织专家,从HPV-B19病原学、流行病学特点、临床表现、诊断、预防、治疗、存在的问题及展望等方面,制订肾移植术后HPV-B19感染的临床诊疗规范,以期为我国肾移植术后HPV-B19感染的规范化防治提供指导。

Long-term use of immunosuppressant in kidney transplant recipients leads to poor immune function and infection with various pathogens.In recent years,along with the advancement of detection technique of human parvovirus B19(HPV-B19)infection and the increasing quantity of kidney transplantation,the infection rate of HPV-B19 after kidney transplantation has been elevated year by year,becoming one of the major causes of pure red cell aplasia,affecting the recovery of renal allograft function,and even leading to the injury or poor prognosis of renal allograft.To further standardize the diagnosis and treatment of HPV-B19 infection in kidney transplant recipients,Branch of Organ Transplantation of Chinese Medical Association and National Kidney Transplantation Quality Control Center jointly organized experts to formulate the clinical diagnosis and treatment specification for HPV-B19 infection after kidney transplantation from the perspectives of etiology,epidemiological characteristics,clinical manifestations,diagnosis,prevention,treatment,existing problems and prospects of HPV-B19,aiming to provide guidance for standardized prevention and treatment of HPV-B19 infection post-kidney transplantation in China.